GemVax pancreatic cancer vaccine misses in Phase III

GemVax & Kael Co. Ltd. (KOSDAQ:082270) said both concurrent and sequential administrations of GV1001 plus standard of care of gemcitabine and capecitabine missed the primary endpoint of improving overall survival (OS) vs. SOC alone in the Phase III TeloVac trial to treat non-resectable pancreatic cancer. The open-label, U.K. trial enrolled 1,062 patients with advanced and metastatic pancreatic cancer. Data were presented at the American Society of Clinical Oncology meeting in Chicago.

GemVax & Kael said it identified two potential biomarkers that may predict an increased survival response in a subgroup of pancreatic cancer patients, but did not disclose details. The company said it plans to initiate new basic research into the mechanisms of action of GV1001 and to test the cancer vaccine targeting human telomerase reverse transcriptase (hTERT) in future clinical trials in a subgroup of patients using the biomarkers. ...